Oral intake of the caffeine metabolite 7-methylxanthine (7-MX), has been associated with reduced myopia progression and reduced axial elongation in a sample of myopic

Stakeholders have until tomorrow night (27 September) to submit their feedback on the refreshed National Medicines Policy that will impact all Australians.

The United States Food and Drug Administration (FDA) has granted de novo premarket approval for Luminopia One as a prescription therapy to improve vision

The Optical Distributors and Manufacturers Association (ODMA) is committed to strengthening, supporting, and growing the optical industry as a whole, while also working to